Rachel Yoder

707 total citations
19 papers, 284 citations indexed

About

Rachel Yoder is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Rachel Yoder has authored 19 papers receiving a total of 284 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cancer Research, 11 papers in Oncology and 3 papers in Pathology and Forensic Medicine. Recurrent topics in Rachel Yoder's work include Breast Cancer Treatment Studies (7 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Rachel Yoder is often cited by papers focused on Breast Cancer Treatment Studies (7 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Rachel Yoder collaborates with scholars based in United States, Australia and Belgium. Rachel Yoder's co-authors include Priyanka Sharma, Alain Mina, Joseph Thornton, Kathleen C. Chambers, Andrew K. Godwin, Anne O’Dea, Joshua M. Staley, Qamar J. Khan, Lauren Nye and Shane R. Stecklein and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and Cancer Research.

In The Last Decade

Rachel Yoder

16 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Rachel Yoder United States	8	154	106	72	49	40	19	284
Irina Kerle Germany	3	166 1.1×	110 1.0×	57 0.8×	110 2.2×	78 1.9×	5	332
Yali Li China	6	70 0.5×	123 1.2×	76 1.1×	63 1.3×	27 0.7×	14	287
Giuseppina Sannino Germany	8	76 0.5×	58 0.5×	57 0.8×	116 2.4×	24 0.6×	10	254
Michael Yourshaw United States	9	48 0.3×	49 0.5×	83 1.2×	166 3.4×	16 0.4×	10	347
Matthieu Martinet France	6	203 1.3×	79 0.7×	19 0.3×	109 2.2×	74 1.9×	14	320
Binya Liu China	12	106 0.7×	139 1.3×	30 0.4×	219 4.5×	59 1.5×	21	420
Tracy J. Litzi United States	3	29 0.2×	49 0.5×	30 0.4×	267 5.4×	12 0.3×	4	373
Liangzhao Chu China	10	27 0.2×	153 1.4×	47 0.7×	191 3.9×	35 0.9×	33	325
Andrew E. Blum United States	8	45 0.3×	28 0.3×	86 1.2×	120 2.4×	25 0.6×	18	301
Rubén Fernández Spain	8	38 0.2×	34 0.3×	25 0.3×	116 2.4×	20 0.5×	16	228

Countries citing papers authored by Rachel Yoder

Since Specialization

Citations

This map shows the geographic impact of Rachel Yoder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rachel Yoder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rachel Yoder more than expected).

Fields of papers citing papers by Rachel Yoder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rachel Yoder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rachel Yoder. The network helps show where Rachel Yoder may publish in the future.

Co-authorship network of co-authors of Rachel Yoder

This figure shows the co-authorship network connecting the top 25 collaborators of Rachel Yoder. A scholar is included among the top collaborators of Rachel Yoder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rachel Yoder. Rachel Yoder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Stecklein, Shane R., Roberto Salgado, Julia White, et al.. (2025). Analysis of the Radiosensitivity Index in Paired Preneoadjuvant and Postneoadjuvant Therapy Triple-Negative Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 124(3). 717–725.

Sharma, Priyanka, Jaimie Heldstab, Rachel Yoder, et al.. (2025). Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC).. Journal of Clinical Oncology. 43(16_suppl). 1094–1094.

Stecklein, Shane R., Roberto Salgado, Anne O’Dea, et al.. (2024). NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology. 42(16_suppl). TPS629–TPS629. 3 indexed citations

Stecklein, Shane R., Rachel Yoder, Joshua M. Staley, et al.. (2024). Abstract PS16-09: Analysis of the Radiosensitivity Index/Genomic-Adjusted Radiation Dose (RSI-GARD) in Paired Pre- and Post-Treatment TNBC Samples: Implications for Biomarker-Guided Radiotherapy. Cancer Research. 84(9_Supplement). PS16–9.

Stecklein, Shane R., Bruce F. Kimler, Rachel Yoder, et al.. (2023). ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease. npj Breast Cancer. 9(1). 10–10. 16 indexed citations

Stecklein, Shane R., Devin C. Koestler, Nanda Kumar Yellapu, et al.. (2023). Extracellular vesicle-derived non-coding RNAs to predict outcome in patients with triple-negative breast cancer (TNBC) with residual disease (RD).. Journal of Clinical Oncology. 41(16_suppl). 578–578. 3 indexed citations

Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2023). Abstract PD11-07: PD11-07 Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials. Cancer Research. 83(5_Supplement). PD11–7. 2 indexed citations

Stecklein, Shane R., Rachel Yoder, Roberto Salgado, et al.. (2023). Abstract PD1-06: Black patients with triple negative breast cancer (TNBC) have enriched stromal tumor infiltrating lymphocytes (sTILs) and receive preferential benefit from neoadjuvant immunotherapy. Cancer Research. 83(5_Supplement). PD1–6. 2 indexed citations

Stecklein, Shane R., Rachel Yoder, Joshua M. Staley, et al.. (2023). Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.. Journal of Clinical Oncology. 41(16_suppl). 507–507. 4 indexed citations

10.

Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2023). Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer. JAMA Oncology. 10(2). 227–227. 78 indexed citations

11.

Sharma, Priyanka, Shane R. Stecklein, Rachel Yoder, et al.. (2022). Clinical and biomarker results of neoadjuvant phase II study of pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer (TNBC) (NeoPACT).. Journal of Clinical Oncology. 40(16_suppl). 513–513. 37 indexed citations

12.

Sharma, Priyanka, Shane R. Stecklein, Bruce F. Kimler, et al.. (2022). Abstract P2-01-05: Impact of post-treatment ctDNA and residual cancer burden (RCB) on outcomes in patients with triple-negative breast cancer (TNBC) and residual disease. Cancer Research. 82(4_Supplement). P2–1. 2 indexed citations

13.

Sharma, Priyanka, Vandana G. Abramson, Anne O’Dea, et al.. (2021). Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). 1076–1076. 16 indexed citations

14.

Larson, Kelsey E., Yen Y. Wang, Rachel Yoder, et al.. (2019). Impact of Germline <i>BRCA</i> Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer. 7(4). 81–81. 1 indexed citations

15.

Sharma, Priyanka, Bruce F. Kimler, Anne O’Dea, et al.. (2019). Results of randomized phase II trial of neoadjuvant carboplatin plus docetaxel or carboplatin plus paclitaxel followed by AC in stage I-III triple-negative breast cancer (NCT02413320).. Journal of Clinical Oncology. 37(15_suppl). 516–516. 7 indexed citations

16.

Mina, Alain, Rachel Yoder, & Priyanka Sharma. (2017). Targeting the androgen receptor in triple-negative breast cancer: current perspectives. OncoTargets and Therapy. Volume 10. 4675–4685. 48 indexed citations

17.

Robinson, Daniel T., Michael S. Caplan, Susan E. Carlson, et al.. (2016). Early docosahexaenoic and arachidonic acid supplementation in extremely-low-birth-weight infants. Pediatric Research. 80(4). 505–510. 13 indexed citations

18.

Chambers, Kathleen C., et al.. (1981). Sexually dimorphic acquisition of a conditioned taste aversion in rats: Effects of gonadectomy, testosterone replacement and water deprivation☆. Physiology & Behavior. 27(1). 83–88. 40 indexed citations

19.

Danowski, T. S., et al.. (1955). SERUM PROTEIN-BOUND IODINE LEVELS FOLLOWING ADMINISTRATION OF THYROXINE IN VARIOUS DISEASES*†. The Journal of Clinical Endocrinology & Metabolism. 15(9). 1116–1130. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact